Abstract
Biological effects of uric acid, generated in the human body either from food or resulting from the purine degradation pathway via xanthine oxidoreductase, are extremely pleiotropic. They are paradoxically opposing under different experimental conditions. Some of these effects are beneficial and some of them are deleterious. The key feature of uric acid is the ability to be either an antioxidant or pro-oxidant depending on a variety of factors. The complexity of the urate chemistry, including its ability to quench or form various radicals, is a crucial component of the mechanisms underlying the ability of uric acid to induce opposing biological effects. In addition, uric acid is a powerful signaling molecule that can affect intracellular signal transduction, leading to oxidant production via nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and expression of proinflammatory mediators. Beneficial antioxidant effects are manifested in the protection of endothelial cells from external oxidative stress and protection of the central nervous system from oxidative damage in several conditions. Detrimental pro-oxidative effects of uric acid are associated with the metabolic syndrome and cardiovascular and renal diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Keilin J. The biological significance of uric acid and guanine excretion. Biol Rev Cambridge Phil Soc 1959;34:265–296
Terkeltaub RA. Gout. N Engl J Med 2003;349:1647–1655
Kellogg EW, III, Fridovich I. Liposome oxidation and erythrocyte lysis by enzymically generated superoxide and hydrogen peroxide. J Biol Chem 1977;252:6721–6728
Proctor P. Similar functions of uric acid and ascorbate in man? Nature 1970;228:868
Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981;78:6858–6862
Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183–1190
Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811–1821
Culleton BF. Uric acid and cardiovascular disease: a renal-cardiac relationship? Curr Opin Nephrol Hypertens 2001;10:371–375
Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Internal Med 1999;131:7–13
Reyes AJ, Leary WP. The ALLHAT and the cardioprotection conferred by diuretics in hypertensive patients: a connection with uric acid? Cardiovasc Drugs Ther 2002;16:485–487
Reyes AJ, Leary WP. The increase in serum uric acid induced by diuretics could be beneficial to cardiovascular prognosis in hypertension: a hypothesis. J Hypertension 2003;21:1775–1777
Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000;148:131–139
Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. Curr Pharm Des 2005;11:4145–4151
Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005;45:18–20
Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008;27:608–619
Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007;293:C584–C596
Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med 1993;14:615–631
Simie M, Jovanovic S. Antioxidation mechanisms of uric acid. J Am Chem Soc 1989;111:5778–5782
Rosell M, Regnstrom J, Kallner A, Hellenius ML. Serum urate determines antioxidant capacity in middle-aged men – a controlled, randomized diet and exercise intervention study. J Intern Med 1999;246:219–226
Maples KR, Mason RP. Free radical metabolite of uric acid. J Biol Chem 1988;263:1709–1712
Vasquez-Vivar J, Santos AM, Junqueira VB, Augusto O. Peroxynitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals. Biochemical J 1996;314(Pt 3):869–876
Santos CX, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys 1999;372:285–294
Hellsten Y, Tullson PC, Richter EA, Bangsbo J. Oxidation of urate in human skeletal muscle during exercise. Free Radic Biol Med 1997;22:169–174
Mikami T, Kita K, Tomita S, et al. Is allantoin in serum and urine a useful indicator of exercise-induced oxidative stress in humans? Free Radic Res 2000;32:235–244
Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002;105:2619–2624
Grootveld M, Halliwell B. Measurement of allantoin and uric-acid in human-body fluids – a potential index of free-radical reactions in vivo. Biochemical J 1987;243:803–808
Kand’ar R, Zakova P, Muzakova V. Monitoring of antioxidant properties of uric acid in humans for a consideration measuring of levels of allantoin in plasma by liquid chromatography. Clin Chim Acta 2006;365:249–256
Felici C, Ciari I, Terzuoli L, et al. Purine catabolism in advanced carotid artery plaque. Nucleosides Nucleotides Nucleic Acids 2006;25:1291–1294
Kahn K, Serfozo P, Tipton PA. Identification of the true product of the urate oxidase reaction. J Am Chem Soc 1997;119:5435–5442
Radi R, Peluffo G, Alvarez MN, Naviliat M, Cayota A. Unraveling peroxynitrite formation in biological systems. Free Radic Biol Med 2001;30:463–488
Robinson KM, Morre JT, Beckman JS. Triuret: a novel product of peroxynitrite-mediated oxidation of urate. Arch Biochem Biophys 2004;423:213–217
Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol 2005;70:343–354
Gersch C, Palii SP, Imaram W, et al. Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids 2009;28:118–149
Kim KM, Henderson GN, Frye RF, et al. Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:65–70
Skinner KA, White CR, Patel R, et al. Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor. J Biol Chem 1998;273:24491–24497
Gersch C, Palii SP, Imaram W, Kim KM, Karumanchi SA, Angerhofer A, Johnson RJ, Henderson GN. Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids 2009;28:118–149
Suzuki T. Nitrosation of uric acid induced by nitric oxide under aerobic conditions. Nitric Oxide 2007;16:266–273
Gersch C, Palii SP, Kim KM, et al. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids 2008;27:967–978
Waugh WH. Inhibition of iron-catalyzed oxidations by attainable uric acid and ascorbic acid levels: therapeutic implications for Alzheimer’s disease and late cognitive impairment. Gerontology 2008;54:238–243
Schlotte V, Sevanian A, Hochstein P, Weithmann KU. Effect of uric acid and chemical analogues on oxidation of human low density lipoprotein in vitro. Free Radic Biol Med 1998;25:839–847
Muraoka S, Miura T. Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol Toxicol 2003;93:284–289
Hink HU, Santanam N, Dikalov S, et al. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 2002;22:1402–1408
Sevanian A, Davies KJ, Hochstein P. Conservation of vitamin C by uric acid in blood. J Free Radic Biol Med 1985;1:117–124
Sevanian A, Davies KJ, Hochstein P. Serum urate as an antioxidant for ascorbic acid. Am J Clin Nutr 1991;54:1129S–1134S
Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 1988;85:9748–9752
Waring WS, Convery A, Mishra V, et al. Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci (Lond) 2003;105:425–430
Waring WS, McKnight JA, Webb DJ, Maxwell SR. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes 2006;55:3127–3132
Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 2001;38:365–371
Kurra V, Eraranta A, Jolma A, et al. Hyperuricemia, oxidative stress, and carotid artery tone in experimental renal insufficiency. Am J Hypertens 2009;22:694–970
Schlesinger I, Schlesinger N. Uric acid in Parkinson’s disease. Mov Disord 2008;23:1653–1657
Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2009;169:1064–1069
Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998;95:675–680
Guerreiro S, Ponceau A, Toulorge D, et al. Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J Neurochem 2009;109:1118–1128
Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 1998;53:613–625
Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull 1994;33:419–425
Hooper DC, Scott GS, Zborek A, et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 2000;14:691–698
Spitsin SV, Scott GS, Mikheeva T, et al. Comparison of uric acid and ascorbic acid in protection against EAE. Free Radic Biol Med 2002;33:1363–1371
Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009;61:885–892
Tsukada K, Hasegawa T, Tsutsumi S, et al. Effect of uric acid on liver injury during hemorrhagic shock. Surgery 2000;127:439–446
Becker BF, Reinholz N, Ozcelik T, Leipert B, Gerlach E. Uric acid as radical scavenger and antioxidant in the heart. Pflugers Arch 1989;415:127–135
Price KL, Sautin YY, Long DA, et al. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 2006;17:1791–1795
Kang DH, Han L, Ouyang X, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 2005;25:425–433
Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett 1999;446:305–308
Sanguinetti SM, Batthyany C, Trostchansky A, et al. Nitric oxide inhibits prooxidant actions of uric acid during copper-mediated LDL oxidation. Arch Biochem Biophys 2004;423:302–308
Imaram W. PhD Thesis, University of Florida 2008
Corry DB, Eslami P, Yamamoto K, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008;26:269–275
Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003;41:1287–1293
Sanchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol 2008;295:F1134–F1141
Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006;58:87–114
Harrison R. Physiological roles of xanthine oxidoreductase. Drug Metab Rev 2004;36:363–375
Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 2004;555:589–606
Galbusera C, Orth P, Fedida D, Spector T. Superoxide radical production by allopurinol and xanthine oxidase. Biochem Pharmacol 2006;71:1747–1752
Spector T. Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol 1988;37:349–352
Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966;275:457–464
Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 2003;42:247–252
Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101–1106
Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol 2002;282:F991–F997
Sanchez-Lozada LG, Tapia E, Lopez-Molina R, et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol 2007;292:F1238–F1244
Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on the blood pressure of adolescents with newly diagnosed essential hypertension. JAMA 2008;300:922–930
George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006;114:2508–2516
Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008–3011
Quinones GA, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995;268:E1–E5
Johnson RJ, Perez-Pozo SE, Sautin YY, et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 2009;30:96–116
Stirpe F, Della Corte E, Bonetti E, et al. Fructose-induced hyperuricaemia. Lancet 1970;2:1310–1311
Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol 2006;290:F625–F631
Reungjui S, Roncal CA, Mu W, et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol 2007;18:2724–2731
Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752–1761
Cheung KJ, Tzameli I, Pissios P, et al. Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab 2007;5:115–128
Perez-Pozo SE, Schold J, Nakagawa T, SÃnchez-Lozada LG, Johnson RJ, Lillo JL. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes (Lond) 2010;34:454–461.
Hsu SP, Pai MF, Peng YS, et al. Serum uric acid levels show a “J-shaped” association with all-cause mortality in haemodialysis patients. Nephrol Dial Transplant 2004;19:457–462
Suliman ME, Johnson RJ, Garcia-Lopez E, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006;48:761–771
Lee SM, Lee AL, Winters TJ, et al. Low serum uric acid level is a risk factor for death in incident hemodialysis patients. Am J Nephrol 2009;29:79–85
Nakagawa T, Mazzali M, Kang DH, et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2–7
Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888–2897
Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol 2002;283:F1105–F1110
Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol 2008;294:F710–F718
Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237–247
Sanchez-Lozada LG, Tapia E, Soto V, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol 2008;108:69–78
Roncal CA, Mu W, Croker B, et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol 2007;292:F116–F122
Kosugi T, Nakayama T, Heinig M, Zhang L, Yuzawa Y, Sanchez-Lozada LG, Roncal C, Johnson RJ, Nakagawa T. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol 2009;297:F481–F488
Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004;44:642–650
Iseki K, Oshiro S, Tozawa M, et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001;24:691–697
Rosolowsky ET, Ficociello LH, Maselli NJ, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin. J Am Soc Nephrol 2008;3:706–713
Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 2009;58:1668–1671
Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000;15:34–42
Ohno I, Hosoya T, Gomi H, et al. Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 2001;87:333–339
Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009;53:796–803
Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51–59
Talaat KM, El-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007;27:435–440
Chao HH, Liu JC, Lin JW, et al. Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells. Acta Pharmacol Sin 2008;29:1301–1312
Cheng TH, Lin JW, Chao HH, Chen YL, Chen CH, Chan P, Liu JC. Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts. Int J Cardiol 2010:139:42–49
Roncal CA, Reungjui S, SÃnchez-Lozada LG, Mu W, Sautin YY, Nakagawa T, Johnson RJ. Combination of captopril and allopurinol retards fructose-induced metabolic syndrome. Am J Nephrol 2009;30:399–404
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Sautin, Y.Y., Imaram, W., Kim, K.M., Angerhofer, A., Henderson, G., Johnson, R. (2011). Uric Acid and Oxidative Stress. In: Miyata, T., Eckardt, KU., Nangaku, M. (eds) Studies on Renal Disorders. Oxidative Stress in Applied Basic Research and Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-60761-857-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-60761-857-7_8
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-856-0
Online ISBN: 978-1-60761-857-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)